ABSTRACT Background and aims: Current systemic therapies for neuroendocrine tumours (NETs) do not provide sufficient control of tumour growth. However, efficient evaluation of novel drugs is hindered by the lack of a suitable preclinical animal model. Here an orthotopic mouse model of pancreatic NET is established and used to study the action of ZK 304709, a first in class, oral multitarget tumour growth inhibitor. ZK 304709 is an inhibitor of cyclin-dependent kinases (Cdks) 1, 2, 4, 7 and 9, vascular endothelial growth factor receptor-type kinases (VEGFRTKs) 1-3 and platelet-derived growth factor receptortype kinase b (PDGF-RTKß). Methods: BON and QGP-1 human NET cells were used to study proliferation, survival and cell cycle distribution in vitro. For induction of orthotopic NETs, BON cells were injected into the pancreas of NMRI nu/nu mice. Primary tumour growth and metastatic spread were recorded after 9 weeks, and apoptosis, microvessel density and lymphatic vessel density were determined. Results: ZK 304709 dose-dependently suppressed proliferation and colony formation of NET cells. Direct effects on NET cells were consistent with Cdk inhibition and involved G 2 cell cycle arrest and apoptosis induction, which was associated with reduced expression of MCL1 (myeloid cell leukaemia sequence 1), survivin and hypoxia-inducible factor 1a (HIF1a). Apoptosis similarly occurred in vivo in ZK 304709-treated orthotopic BON tumours, resulting in a 80% reduction of primary tumour growth. In contrast, treatment with lanreotide or 5-fluorouracil and streptozotocin failed to inhibit tumour gowth. ZK 304709 also reduced tumour microvessel density, implicating antiangiogenic mechanisms. Conclusion: BON orthotopic tumours provide an informative model for preclinical drug evaluation in NETs. In this model, ZK 304709 achieved efficacious tumour growth control via induction of apoptosis and inhibition of tumour-induced angiogenesis.
Palliative management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) currently relies on biotherapy with somatostatin analogues and interferon a, on chemotherapy and on chemoembolisation of liver metastases. 1 Given the low response rates and/or considerable side effects of these modalities, improved treatment options are needed.
Cyclin-dependent kinases (Cdks) have attracted considerable interest as drug targets in oncology. 2 Cdks comprise a family of serine-threonine kinases with two major functions: they serve either as core components of the cell cycle machinery, where they promote and control transit between distinct cell cycle phases, or as regulators of RNA polymerase II activity, which participates in transcription control. Although perturbations of individual Cdks result in cell cycle arrest of tumour cells, 3 4 recent studies indicated an unforeseen redundancy of Cdk-cyclin interactions. [5] [6] [7] [8] Moreover, apoptosis following pharmacological Cdk inhibition probably resulted from inhibition of transcriptional Cdks rather than cell cycle perturbation. 9 In view of these findings, the paradigm of the ideal therapeutic Cdk inhibitor has shifted from a highly selective inhibitor of an individual Cdk towards a compound that targets multiple members of the Cdk family with different functions. 2 ZK 304709 is an oral small molecule kinase inhibitor of Cdks 1, 2, 4, 7 and 9 at nanomolar concentrations. 10 In addition to these ubiquitous targets, ZK 304709 blocks the activity of vascular endothelial growth factor receptor-type kinases (VEGF-RTKs) 1-3 and platelet-derived growth factor receptor-type kinase b (PDGF-RTKß) expressed on endothelial cells, thereby adding an antiangiogenic and possibly antilymphangiogenic action profile in vivo. Given the molecular heterogeneity 11 and abundant vascularisation 12 that represent well-established features of NETs, the multitargeted profile of ZK 304709 seems ideally suited for antitumour action in these malignancies.
Currently the lack of a reliable and representative animal model of GEP-NET disease limits an efficient preclinical evaluation of experimental therapeutics. Here, we established an orthotopic in vivo model of pancreatic neuroendocrine cancer and used this model to evaluate the therapeutic effects of ZK 304709.
MATERIALS AND METHODS
Antibodies were from the following sources: poly(ADP) ribose polymerase (PARP) from Oncogene Research Products (Bad Soden, Germany); pRb, cyclin E and CD34 from BD Pharmingen (Heidelberg, Germany); cdc2, cdk2 and human pancytokeratin (C11) from Santa Cruz Corporation (Santa Cruz, California, USA); survivin, hypoxia-inducible factor 1a (HIF1a) from R&D Systems GmbH (Wiesbaden-Nordenstadt, Germany); cyclin A, MPM2 (mitotic protein monoclonal 2) and myeloid cell leukaemia sequence 1 (MCL1) from Upstate Biotechnology (Charlottesville, Virginia, USA); synaptophysin and chromogranin A (CgA) from DAKO (Hamburg, Germany) and lymphatic vessel endothelial hyaluronan receptor (LYVE-1) from Relia Tech (Braunschweig, Germany). Secondary antibodies and anti-human Ki67 were from Dianova (Hamburg, Germany). Nocodazole, streptozotocin (STZ), fluorouracil (5-FU) and 49,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma (Deisenhofen, Germany). Rompun was from Bayer GmbH (Leverkusen, Germany), Ketavet from Pharmacia GmbH (Erlangen, Germany) and lanreotide (SOMATULINE Autogel) was from Ipsen Pharma GmbH (Ettlingen, Germany).
Cell culture BON cells 13 were a generous gift from C M Townsend (Galveston, Texas, USA). QGP-1 cells were from the Health Science Research Resources Bank (Osaka, Japan). Both cell lines were derived from metastasised pancreatic NETs, but differ with respect to functionality and molecular alterations. Of note, QGP-1 cells are functionally deficient for the tumour suppressor pRb and BON cells for p16 ink4a . 14 15 16 Cells were cultured as described. 16 
Growth assays
Cells were plated in 96-well dishes at 2500 cells/well. At the indicated times, viable cells were counted in a haemocytometer. Clonal growth of NET cells was examined as described. 16 
Flow cytometry and immunofluorescence
For cell cycle analyses, adherent and detached cells were collected and DNA content was determined on a FACSCalibur utilising ''Cellquest'' software (Becton Dickensen, Heidelberg, Germany) as described. 14 For MPM2 staining, cells were incubated with 1 mg/ml MPM2 antibody prior to propidium iodide staining. To assess nuclear morphology, cells were stained with 1 mg/ml DAPI after methanol-acetone fixation and examined using a Zeiss Axioplan.
Immunoblotting
A total of 5610 6 cells were lysed in 1 ml of RIPA buffer supplemented with protease inhibitors and processed as previously described. 16 For immunoblotting of PARP, 10 6 cells were lysed in 250 ml of urea buffer. 17 Nuclear extracts were prepared using a non-ionic detergent method. 18 
Tumour implantation
Female NMRI nu/nu mice (21-25 g) were from Bomholtgard (Ry, Denmark). Animal care followed institutional guidelines and experiments were approved by local animal research authorities. Mice were anaesthetised by intraperitoneal administration of Ketavet (100 mg/kg) and Rompun (10 mg/kg). For tumour induction, the pancreas was exposed and 1610 6 BON cells were injected into the head of the pancreas. After 9 weeks, mice were killed, blood samples were collected and primary tumours were removed and weighed. Tumour volume was calculated using the formula length 6 width 6 depth 6 p/6. Enlarged lymph nodes and macroscopically evident metastases were collected for histology. Also, liver tissue and liver hilus lymph nodes were routinely obtained.
Histochemical analyses
Cryostat sections (4 mm) of murine tissues were fixed in 4% paraformaldehyde, pH 7. Immunoperoxidase staining was performed with an avidin-biotin complex method (Vectastain Elite ABC kit, Vector Laboratories, Wertheim-Bettingen, Germany) using 3-amino-9-ethylcarbazole (AEC, DAKO, Hamburg, Germany) substrate. Antibody dilutions were: CD31, 1:100; pancytokeratin, 1:50; LYVE-1, 1:200; CgA, 1:300; and synaptophysin, 1:100. Apoptotic cells were identified by terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assay using the TumorTACS in situ Apoptosis Detection Kit (R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany). Primary antibodies or terminal deoxynucleotidyl transferase, respectively, were omitted in negative controls. Quantitative immunohistochemical analysis was carried out using Axiovision 4.2 software (Zeiss, Jena, Germany). 
Determination of microvessel density and lymphatic microvessel density
For quantitation of microvessel density (MVD) and lymphatic vessel density, respectively, the average number of CD34-and LYVE-1-positive vessels in a 0.6 mm 2 measurement area was determined from three regions of maximal vascular density (vascular hotspots). 19 Determination of chromogranin A serum concentration Serum CgA levels were measured using a CgA ELISA Kit (Dako Cytomation GmbH) as recommended by the manufacturer.
Statistical analysis
Data analysis was performed by analysis of variance (ANOVA) utilising the Newman-Keuls test, Mann-Whitney or Fisher exact test (graph pad software, San Diego, California, USA). Differences were considered significant at p,0.05.
RESULTS
ZK 304709 inhibits anchorage-dependent and anchorageindependent growth of human NET cells
The kinase inhibition profile of ZK 304709 has been extensively characterised in cell-free systems, but potential mechanisms of antitumour action still await confirmation at the cellular level. Treatment of human pancreatic NET cell lines with 500 nM ZK 304709 for 72 h severely reduced cell numbers, whereas 100 nM octreotide had only minor effects ( fig 1A) . Growth inhibition was concentration dependent, with a calculated EC 50 (median effective concentration) of 129 nM for BON and 79 nM for QGP-1 cells (fig 1B) . At 500 nM, ZK 304709 reduced cell numbers even below initial numbers, suggesting that cell death occurred.
We next evaluated colony formation in agar suspension ( fig 1C) . ZK 304709 suppressed colony formation by approximately 95%, with EC 50 values comparable with those in the proliferation studies.
Thus, ZK 304709 elicited profound growth inhibitory effects at concentrations compatible with inhibition of Cdk complexes in biochemical kinase assays. Taken together, DNA histograms and regulatory changes of cyclins supported an inhibition of Cdc2 and Cdk2 complexes, as was expected from the action profile of ZK 304709 in cell-free assays.
ZK 304709-induced apoptosis is associated with the depletion of endogenous apoptosis inhibitors
Apoptosis induction by Cdk inhibitors has been linked to inhibition of transcriptional Cdks with subsequent depletion of short-lived apoptosis inhibitors such as MCL1. Immunoblot analysis of MCL1 expression in ZK 304709-treated NET cells indeed illustrated a rapid decrease (45% (6.1%) of control in BON and 31% (9.5%) of control in QGP-1 cells, p,0.05 at 6 h, fig 4B, left) , which persisted throughout 48 h (fig 4B, right) .
Survivin represents a second apoptosis-protective target of Cdk inhibitors. Again, immunoblot analyses revealed a reduction of cellular survivin content in both NET lines, with a maximal inhibition to 33% (7.9%) of the control observed at 24 h in QGP-1 cells and to 55% (3.6%) at 48 h in BON cells (p,0.05, data not shown). Because nuclear, but not cytoplasmic survivin expression was linked to prognosis of NETs in immunohistochemical studies, 21 we separately analysed both compartments. Upon ZK 304709 treatment, the survivin complement of the nuclear fraction decreased in both cell lines ( fig 4C) .
More recently, the transcription factor HIF1a was identified as a potential target of Cdk inhibitors. 22 HIF1a mediates adaptive responses to hypoxia and to the tumour cell's increased energy demand, and thereby contributes to apoptosis protection. HIF1a protein was easily detected in nuclear extracts of NET cells under normoxia and accumulated following chemical induction with CoCl 2 ( fig 4D) . Upon treatment with ZK 304709 for 16 h, basal levels of HIF1a declined to 36% (8%) of control in QGP-1 cells and to 56% (9%) in BON cells (n = 3-4, p,0.05). In contrast, HIF1a stabilisation due to hypoxia or CoCl 2 remained unaffected (data not shown). Overall, ZK 304709-mediated depletion of multiple apoptosis inhibitors probably facilitated apoptosis induction by lowering the apoptotic threshold.
BON orthotopic tumours in mice represent a useful model system to study NET biology Based on these encouraging results, we addressed the antitumour action of ZK 304709 in vivo. In contrast to the in vitro situation, we anticipated a relevant contribution of the ability of ZK 304709 to inhibit proangiogenic receptors. Accordingly, an in vivo model, which permitted examination of primary tumour growth, tumour neoangiogenesis and metastatic spread, seemed mandatory.
We therefore adapted the procedure for orthotopic xenografting of exocrine pancreatic cancer cells 23 and implanted human pancreatic BON NET cells, known to form subcutaneous tumours in nude mice 13 16 18 24 into the pancreas of NMRI nu/nu mice. Following implantation, we monitored tumour growth at 5, 7 and 9 weeks (fig 5A,B) . Tumours developed in .90% of animals. By 9 weeks, they had reached .300 mg average weight, and individual tumours presented with signs of locally invasive growth into adjacent duodenal or gastric tissues and Ki67 fractions ranging from 1% to 7% of cells (median 2.4). Orthotopic BON tumours retained markers of neuroendocrine differentiation such as CgA and synaptophysin ( fig 5C) . 
BON orthotopic NETs model metastatic disease
Besides the primary tumour, suspect intra-abdominal lesions were recorded, suggesting that metastasis occurred (fig 6) . (fig 6A,B) , although additional locations (eg, peritoneum) were noted in individual cases.
ZK 304709 inhibits tumour growth in BON orthotopic NETs
Having established BON orthotopic tumours as an appropriate in vivo model, we evaluated the antitumour potential of ZK 304709. Tumours were allowed to grow for 2 weeks, before animals were randomly assigned to either the treatment group (100 mg/kg/day ZK 304709 orally), a control group (vehicle) or to a section group, which was sacrificed at the start of the treatment in order to determine average tumour burden. Treatment continued for 7 weeks, until mice were sacrificed. By that time, tumour weight in the treatment group was significantly reduced (fig 7A) , which was reflected by decreased tumour volumes (113.5 (25.92) mm 3 vs 611.7 (96.33) mm 3 in controls, p,0.01) and a reduction in the plasma CgA concentration ( fig 7B) . Furthermore, fewer ZK 304709-treated animals presented macrometastases (fig 7C) , although the difference did not reach statistical significance due to the small number of animals that could be evaluated. We then sought to compare the efficacy of ZK 304709 with that of established treatment modalities. Thus, nude mice bearing BON tumours received either ZK 304709 as described above, or lanreotide or a combination chemotherapy of 5-FU and STZ. Drug dosage and application schedule followed the protocol used for palliative treatment of NETs, with the notable exception of STZ, which causes severe b-cell toxicity in mice and was accordingly reduced in order to avoid diabetes induction. Both lanreotide and 5-FU/STZ treatment were well tolerated, as judged based on comparable body weights (not shown), but did not delay tumour growth, whereas ZK 304709 had again significantly reduced tumour burden ( fig 7D) .
ZK 304709 induces tumour cell apoptosis in BON orthotopic NETs
Given the convincing antitumour action of ZK 304709, we aimed to outline mechanisms that acted in vivo. A relevant contribution of apoptosis was evident from in situ TUNEL staining, which documented a sixfold increased apoptotic index in tumours from the treatment group (fig 8A, left) .
ZK 304709 reduces microvessel density of BON orthotopic NETs
In order to assess whether ZK 304709 affected tumour growth indirectly by targeting the endothelial compartment, MVD and lymphatic vessel density were determined via immunohistochemical detection of CD34 and LYVE-1, respectively ( fig 8B) . A significant reduction of MVD had occurred in ZK 304709-treated animals, indicating an inhibition of tumourangiogenesis (fig 8B upper panel) . A similar trend was noted for lymphatic vessel density, though the reduction failed to reach statistical significance ( fig 8B, lower panel) .
DISCUSSION
Despite improved clinical management of GEP-NETs, treatment modalities do not yet provide satisfactory control of tumour growth.
1 Two obstacles impede progress: first, low proliferation rates account for poor responses to conventional chemotherapies and a narrow therapeutic window. Secondly, the molecular diversity of NETs has until recently precluded the identification of disease-specific molecular alterations, 11 25 which could then translate into the development of a specific targeted drug.
Between these limitations, a number of targeted therapies, which interfere with specific components of commonly altered proangiogenic, mitogenic and antiapoptotic signalling pathways, are currently being tested as single agents or in combination (http://www.cancer.gov/clinicaltrials).
We pursued a different approach, using the multitargeted kinase inhibitor ZK 304709, which acts on multiple Cdks and on endothelial RTKs. ZK 304709 has shown superior antitumour efficacy in diverse xenograft models including breast, colonic, pancreatic and kidney cancer when compared with standard chemotherapy, 10 and has recently undergone phase I clinical trials. In NET cells, ZK 304709 inhibited growth at nanomolar concentrations in vitro, via mechanisms that involved G 2 cell cycle inhibition and induction of apoptosis. These effects translated into tumour cell apoptosis and inhibition of tumourangiogenesis in an orthotopic mouse model of NET disease, resulting in a profound reduction of tumour burden.
Unlike earlier concepts on the use of Cdk inhibitors, which aimed to re-establish pRb-like checkpoint control via inhibition of G 1 kinases, recent insights into cell cycle control of tumour cells advocate a combination approach targeting both Cdk2 and Cdc2, leading to cell cycle arrest in the G 2 phase. 2 9 26 In fact, such a pattern of G 2 accumulation occurred in ZK 304709-treated NET cells at drug concentrations which inhibited both Cdk2 and Cdc2 in biochemical kinase inhibition studies. 10 Cell cycle effects did not differ between pRb-competent BON cells, and pRb-deficient QGP-1 cells, indicating that Cdk4/Cdk2-mediated, pRb-dependent mechanisms were dispensable for the cell cycle inhibitory activity of ZK 304709.
Apart from the G 2 cell cycle arrest, ZK 304709 induced apoptosis, and thus converted a reversible inhibition of Cdk activity into irreversible tumour cell death. Apoptosis following Cdk inhibition potentially results from deregulated, increased E2F activity, [27] [28] [29] or from inhibition of the transcriptional Cdks 7 and/or 9. 30 31 Complexed to cyclin H and cyclin T, respectively, Cdks 7 and 9 activate RNA polymerase II. Therefore, their inhibition leads to depletion of short-lived mRNAs 32 including apoptosis inhibitors, as was shown for the antiapoptotic bcl-2 family member MCL1 following pharmacological ablation of Cdk9 activity by either flavopiridol or r-roscovitine. 30 31 33 In NET cells we similarly noted an early and persistent reduction of MCL1 following ZK 304709 treatment, suggesting that the drug affected the balance of proapoptotic and antiapoptotic bcl-2 family members and thereby lowered the apoptotic threshold. While the biological significance of MCL1 regulation in NETs is unclear, nuclear expression of the apoptosis inhibitor survivin has been connected to poor differentiation and metastasis of NETs. 21 We found survivin expressed in both NET cell lines in the nuclear and the cytosolic compartment and noted a reduction upon ZK 304709 exposure, an effect which may have contributed to the altered apoptotic threshold observed. Reduced expression of survivin by Cdk inhibitors was previously proposed to result from transcriptional inhibition and/or increased proteasomal degradation, possibly a consequence of cdc2 inhibition. 33 34 We also observed an inhibition of nuclear HIF1a expression in ZK 304709-treated cells under normoxic conditions, when HIF1a's presence may depend on oncogene-driven transcriptional control rather than protein stabilisation. Given that flavopiridol downregulated HIF1a via proteasome-independent mechanisms in human glioma cells, 22 HIF1a may represent a common target of Cdk inhibitors, though the exact mechanism and the functional relevance of HIF1a reduction in NETs remain to be determined.
Considering that ZK 304709 affected multiple and diverse signalling pathways, its almost uniform in vitro action in BON and QGP-1 cells is notable, since both cell lines differ in their molecular profile with respect to the tumour suppressors p16 14 and pRb, 15 to bcl-2 35 and to transforming growth factor b effectors. 36 Their comparable responsiveness to ZK 304709 thus supports the concept of targeting the core cell cycle and transcription machinery in molecularly heterogeneous malignancies such as NETs.
Based on our in vitro data, apoptosis induction represented an integral aspect of the growth-inhibitory action of ZK 304709 and converted a reversible inhibition of Cdk activity into irreversible tumour cell death. Even more importantly, tumour cell apoptosis represented a relevant antitumour mechanism in vivo at drug concentrations achieved by oral application of ZK 304709. In contrast, we found no evidence for apoptotic cell death in the liver or residual non-transformed pancreatic tissue, consistent with the proapoptotic mechanisms operating predominantly in transformed cells.
In addition to apoptosis, we noted a reduction of MVD in treated animals. As BON cells express and secrete high levels of VEGF-A, 18 and ZK 304709 can block signalling via VEGFR1 and 2, this observation conceivably reflected a disruption of proangiogenic VEGF-A signalling. Lymphangiogenic signalling via VEGFR3 should similarly be compromised by ZK 304709 treatment. Major VEGFR3 ligands are VEGF-C and VEGF-D, which are both prominently expressed in non-transformed neuroendocrine cells, suggesting a physiological role in neuroendocrine differentiation. In a large series of human pancreatic NET specimens, overexpression of VEGF-C, but not VEGF-D expression, was specifically associated with lymphangiogenesis and lymph vessel invasion, which occurred more frequently in angioinvasive/metastatic tumours. 37 Thus, reduction of lymphangiogenensis possibly constitutes an added clinical benefit of pharmacological inactivation of VEGFR3 by ZK 304709. In the current study we noted a trend toward lymphatic vessel density reduction, raising the possibility that a reduction of lymph vascularisation contributed to the antitumour action of ZK 304709 in some mice.
While the concept of an antiangiogenic treatment for NETs is accepted as particularly promising, clinical results have remained ambiguous. For instance, endostatin failed in a phase II trial in pancreatic NETs, 38 although the substance was highly efficacious in the rip-tag model of multistep islet cell carcinogenesis. An intriguing challenge is, furthermore, provided by the inverse correlation of MVD and disease progression reported from clinical specimens of pancreatic NETs. 12 Thus, additional in vivo models of NETs may prove helpful in both preclinical drug testing and dissecting the biology of NET vascularisation.
The current orthotopic model uses a representative human NET cell line in a microenvironment which offers an organtypical interaction between the tumour cells, the stroma, the vascular compartment and the drug. [39] [40] [41] Thus, it provides a hitherto unique opportunity to study context-driven aspects of human NET biology and drug response, such as metastasis, which cannot be addressed in the subcutaneous setting. Neither lanreotide biotherapy nor 5-FU/STZ chemotherapy were able to control tumour growth in this orthotopic model, reflecting the unresolved medical needs of advanced metastatic pancreatic NETs, Our first preclinical evaluation of a novel treatment modality in this model suggests ZK 304709 as an attractive treatment alternative for human NETs. 
